Alumis (ALMS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
The annual meeting will be held virtually on June 30, 2026, to elect three Class II directors and ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
Only stockholders of record as of May 5, 2026, are entitled to vote, with 123,432,072 shares of voting common stock outstanding.
Voting can be done online, by phone, by mail, or during the virtual meeting; votes are counted by Broadridge Financial Solutions.
Stockholder proposals for the 2027 annual meeting must be submitted by January 18, 2027, for inclusion in proxy materials.
Voting matters and shareholder proposals
Proposal 1: Election of three Class II directors (James B. Tananbaum, Lynn Tetrault, Zhengbin Yao) to serve until 2029.
Proposal 2: Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Board recommends voting “FOR” all director nominees and auditor ratification.
Shareholders may submit proposals for the 2027 meeting by January 18, 2027, or nominate directors between March 2 and April 1, 2027.
Board of directors and corporate governance
Board consists of eight members divided into three classes, with staggered three-year terms.
Majority of directors are independent under Nasdaq rules; only the CEO is not independent.
Board leadership combines CEO and Chairman roles, with a lead independent director appointed in June 2025.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.
Board and committees conduct annual self-evaluations; directors are assessed for overboarding.
Code of Business Conduct and Ethics and an insider trading policy are in place.
Latest events from Alumis
- Envudeucitinib advances in psoriasis and targeted lupus populations, with new CNS and pipeline programs progressing.ALMS
Wells Fargo 21st Annual Healthcare Conference - Envudeucitinib showed strong efficacy in IFNGS-high SLE patients, supporting Phase 3 focus.ALMS
Study result - Envudeucitinib and A-005 deliver leading efficacy in immune diseases, targeting $180B+ markets.ALMS
Corporate presentation - Envudeucitinib set a new efficacy benchmark in psoriasis; Q2 net loss was $142.2M with $502.3M cash.ALMS
Q2 2026 - Election of three directors and auditor ratification to be decided at June 2026 virtual meeting.ALMS
Proxy filing - Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise potential.ALMS
Corporate presentation - Envudeucitinib's Phase 3 success drives NDA plans as $569.5M cash supports operations into 2027.ALMS
Q1 2026 - Envudeucitinib achieved rapid, sustained skin clearance and symptom relief with strong safety in Phase 3 trials.ALMS
Study update - Envudeucitinib achieved top Phase 3 results in psoriasis, driving a high-value, multi-indication pipeline.ALMS
Corporate presentation